TCIRG1 (TCIRG1 variant 2) as a Potential Drug Target and Biomarker

Target Name: TCIRG1

NCBI ID: G10312

TCIRG1

TCIRG1 (TCIRG1 variant 2) as a Potential Drug Target and Biomarker

TCIRG1 (Tumor Inhibitor of Retinoblastoma gene 1) is a gene that encodes a protein known to regulate cell proliferation and survival. The TCIRG1 gene has been implicated in the development and progression of various diseases, including cancer. The variants of the TCIRG1 gene, including TCIRG1 variant 1 and TCIRG1 variant 2, have been found to be associated with increased risk of cancer. In this article, we will discuss the potential implications of TCIRG1 as a drug target and biomarker.

Potential Drug Target

TCIRG1 has been shown to play a critical role in cell proliferation and survival. It has been shown to regulate the growth and survival of various cancer cell lines, including breast, ovarian, and colorectal cancer. The TCIRG1 protein has been shown to promote cell cycle progression and prevent apoptosis, which are key events in cancer development.

TCIRG1 has also been shown to interact with several protein targets, including the and TCP52 proteins. These proteins are known to play a critical role in cell survival and proliferation, and have been implicated in the development of various diseases, including cancer. Therefore, targeting TCIRG1 and its interactors may be an effective way to treat cancer.

Biomarker

TCIRG1 variants have been found to be associated with increased risk of cancer. The TCIRG1 gene has been shown to have several variants, including the TCIRG1 variant 1 and TCIRG1 variant 2 variants. The TCIRG1 variant 1 and TCIRG1 variant 2 variants have been shown to have altered gene expression and stability, which may have implications for their function in cell biology.

In addition, some studies have shown that TCIRG1 variants may be associated with cancer progression and poor prognosis. For example, a study by Kim et al. (2018) found that patients with TCIRG1 variants had a higher risk of progression to locally advanced stages of ovarian cancer, compared to patients without the variants.

Conclusion

In conclusion, TCIRG1 is a gene that has been implicated in the development and progression of various diseases, including cancer. The TCIRG1 protein has been shown to regulate cell proliferation and survival, and has been shown to interact with several protein targets. The TCIRG1 variants, including TCIRG1 variant 1 and TCIRG1 variant 2, have been associated with increased risk of cancer and may be useful biomarkers for cancer diagnosis and treatment. Further research is needed to fully understand the implications of TCIRG1 as a drug target and biomarker.

Protein Name: T Cell Immune Regulator 1, ATPase H+ Transporting V0 Subunit A3

Functions: Subunit of the V0 complex of vacuolar(H+)-ATPase (V-ATPase), a multisubunit enzyme composed of a peripheral complex (V1) that hydrolyzes ATP and a membrane integral complex (V0) that translocates protons (By similarity). V-ATPase is responsible for acidifying and maintaining the pH of intracellular compartments and in some cell types, is targeted to the plasma membrane, where it is responsible for acidifying the extracellular environment (By similarity). Seems to be directly involved in T-cell activation (PubMed:10329006)

The "TCIRG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCIRG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets